ATP-dependent mitochondrial protease YME1L1 (YME1L1) (YME1L1)

ATP-dependent mitochondrial protease YME1L1 (YME1L1) is a nuclear-encoded enzyme located in the inner mitochondrial membrane that plays a pivotal role in maintaining mitochondrial proteostasis and morphology (UniProt: Q96TA2). As a member of the AAA+ ATPase family, it functions by degrading misfolded proteins within the intermembrane space and performing the regulated proteolytic cleavage of OPA1, a GTPase essential for mitochondrial fusion and cristae maintenance (Song et al., 2007, PMID: 17706237). This processing of OPA1 is critical for balancing mitochondrial dynamics, and its disruption is a hallmark of various mitochondrial pathologies. Mutations in the YME1L1 gene are clinically linked to a syndrome characterized by mitochondrial encephalopathy, optic atrophy, and intellectual disability, highlighting its necessity for neurological function (Hartmann et al., 2016, PMID: 27453444). In the context of oncology, YME1L1 has been identified as a factor that supports the metabolic adaptation of cancer cells, particularly under conditions of nutrient deprivation or hypoxia, by regulating the mitochondrial proteome (MacVicar et al., 2019, PMID: 31123219). While there are currently no FDA-approved drugs targeting YME1L1, it is an area of active research for therapeutic modulation of mitochondrial health. However, the essential nature of its role in cellular energy production presents significant safety challenges, as systemic inhibition could lead to widespread mitochondrial dysfunction and organ failure.

Other names

Yeast mitochondrial escape 1-like 1YME1LPAMPMeg-4FTSHYME1-like protein 1

No current clinical drugs; hypothetical mechanisms involve inhibition of protease activity to modulate mitochondrial dynamics and proteostasis.